Edna F. Choo
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Protein Degradation and Inhibitors, Computational Drug Discovery Methods, Pharmacogenetics and Drug Metabolism, Prostate Cancer Treatment and Research
Most-Cited Works
- → THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL(2004)440 cited
- → Pharmacological Inhibition of P-glycoprotein Transport Enhances the Distribution of HIV-1 Protease Inhibitors into Brain and Testes(2000)394 cited
- → A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation–Driven Colorectal Tumor Growth(2013)318 cited
- → Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression(2009)172 cited
- → Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer(2017)149 cited
- → Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models(2020)138 cited
- → Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response(2012)130 cited
- → Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL Inhibitor(2020)127 cited
- → GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP)(2017)126 cited
- → Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300(2016)94 cited